Media Inquiries

If you are interested in interviewing a CCR scientist, OR you are a scientist who has been contacted by a member of the media, please contact the NCI Press Office at ncipressofficers@mail.nih.gov or by phone at 240.760.6600.

News and Events

Celebrating CCR Careers: Steven Z. Pavletic, M.D., Ph.D.

Steven Z. Pavletic, M.D., Ph.D., is a renowned expert in chronic graft-versus-host disease, a serious late complication that can happen after allogeneic bone marrow transplants. After serving at the NCI for over 20 years, he is now announcing his retirement.

Clinical trial researching neuroendocrine neoplasms

A clinical trial led by Jaydira Del Rivero, M.D., Associate Research Physician in the Developmental Therapeutics Branch, is researching the biology of neuroendocrine neoplasms.

Clinical trial researching therapy for neuroendocrine cancer

A clinical trial led by Jaydira Del Rivero, M.D., Associate Research Physician in the Developmental Therapeutics Branch, is researching a combination drug therapy for neuroendocrine cancer.

Celebrating CCR Careers: William G. Stetler-Stevenson, M.D., Ph.D.

For over three decades, William G. Stetler-Stevenson, M.D., Ph.D., has been a leader in the field of tissue inhibitors of metalloproteinases (TIMP) biology and extracellular matrix regulation of cancer.

Celebrating CCR Careers: Allan M. Weissman, M.D.

Allan M. Weissman, M.D., who explored the essential underpinning of ubiquitin in cancer, announces his retirement from the NCI.

Celebrating CCR Careers: Kathleen Kelly, Ph.D.

Kathleen Kelly, Ph.D., who pioneered new frameworks for modeling and exploring how prostate cancer cells respond to anti-cancer drugs, announces her retirement from the NCI.

PROTACtion against resistance of commonly used anti-cancer drug

Drugs known as PIM kinase inhibitors are used to treat a range of cancers, but many patients develop resistance to these medications. Recent research has led to a new class of therapeutics that target the mechanism of this resistance, resulting in increased death of cancer cells.

Celebrating CCR Careers: Kenneth H. Kraemer, M.D.

For more than fifty years, Kenneth H. Kraemer, M.D., has investigated the molecular underpinnings and clinical manifestations of xeroderma pigmentosum, a rare disease that makes children highly vulnerable to skin damage and cancers from ultraviolet radiation, at the NCI.

Molecular signature can identify tumor-targeting immune cells in the blood

Blood samples could be a new source of antitumor T cells for customized cancer immunotherapies.

Clinical trial researching olfactory neuroblastoma

A clinical trial led by Charalampos S. Floudas, M.D., D.M.Sc., M.S., Assistant Research Physician in the Center for Immuno-Oncology, is researching the symptoms and characteristics of olfactory neuroblastoma.

tumor cells, immune cells, and dead cells

Novel T cell stimulation technique drives potent anti-tumor response

Researchers combined an antibody with an immune-signaling molecule resulting in an agent called STAR0602. A version of the novel agent was designed for and tested in mice, which induced significant tumor shrinkage and increased survival across six different types of cancer while exhibiting little toxicity. The promising lab findings have prompted the launch of a clinical trial in people.

Breadcrumb

News and Events